Skip to main content
Metallomix
Metallomix

  • Disease modifying therapies that repair cellular functions

Dr. Sergei Petukhov, DVM

Co-Founder & CEO

Welcome to Metallomix 

We are out-of-the box thinkers who develop the isotope-selective modulation platform that empowers creating breakthrough therapies for unmet medical needs.
​With that mission in mind, we live and work to extend and expand our proprietary research of isotopic signatures in biological cells and tissues, and to develop a pipeline of novel therapeutics that helps people live better for longer.    

Current Focus on 64Zn Isotope

Targeting isotopic dysfractionation of zinc via multiple pathways without suppressing the immune system

Oncology

Ongoing Phase 1/2 Clinical Trials in malignant neoplasms and CLL

Metabolic

Preparing for Phase 1 clinical trial in Type 2 Diabetes and NAFLD

Neurology

Preparing for Phase 1 clinical trials in PD, LBD, and AD

Autoimmune

Designing animal studies for MS and Hashimoto disease

Our anti-tumor drug candidate, Aspazin has shown a potential for regulating the immune response that could eradicate solid tumors and blood cancers.
​(Currently in human clinical trials)

Our Purpose

We live and work to develop safe and effective cold isotope therapies that will help people to live better for longer.

Our Mission

We aim to become the world-leading metallogenomic biotech company focused on the role of isotopic metallome.

Our Science

We continue to expand our discovery of isotope-selective modulation and its effects on repairing cellular functions. 

Our Results

We attained the initial proof of concept that isotope-selective modulation may repair cellular processes and homeostasis.

Our drug candidate, Isotozin, has shown neuroprotective effect and the ability to decrease neuroinflammation and oxidative stress without suppressing the immune system.        
​​(Now preparing for human clinical trials)

ISM Drug Development Platform

Our expertise is centered around the integration of Metallomics and pharmaceutical development, focusing on the role and function of isotopic fractionation and roles of stable isotopes within metalloproteomics. Unlike conventional medications that typically interact with their targets on a surface level, thereby managing symptoms rather than the root cause, our isotope-selective modulation, in conjunction with a multi-omic approach, empowers us to create drugs that holistically influence critical biological processes, ranging from protein synthesis and DNA repair to mitochondrial function, and reduction of local any systemic inflammation and oxidative stress.

Our NAFLD drug candidate, Omazinc, has shown a strong potential for reducing fat deposits in liver, while regulating insulin sensitivity and helping to reduce body weight while maintaining muscle mass and increasing serotonin levels.
​(Now preparing for human clinical trials)

Making The Difference

Inflammation and oxidative stress play important roles in the development of several chronic conditions affecting many organs. These conditions are interconnected and intensify one another, thus fueling a "snowball" effect that accelerates the progression of many dysfunctions leading to life-threatening diseases.
Metallome deficiencies in general, and isotopic fractionation in particular, may induce chronic pro-inflammatory state and oxidative stress, also impairing protein folding and stability, mitochondrial and lysosomal functions, and other vital processes, which offers new and unique way for modern science to perceive degeneration and ageing.                        

Isotopically enriched zinc-64 plays a critical role in reducing inflammation and oxidative stress via several mechanisms of action, which renders a therapeutic effect on many vital organs.

Our goal is to become the world's leader in isotopic metallomics focused on developing inherently safe, effective, and clinically derisked, disease modifying therapies for treatment of complex diseases.